<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.3.0">

  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Adam La Caze">

  
  
  
    
  
  <meta name="description" content="BACKGROUND: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.  METHODS: We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS) subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred in May 2007. The DDD/1000 population/day were examined in a series of time-series regression analysis with the drug safety warnings specified as interventions.  RESULTS: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000 population/day in January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value &lt;0.001), however use did not significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009-2010. However, pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.  CONCLUSIONS: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/niyomnaitham-2014/">

  


  

  

  

  

  

  

  
  
  
  <meta name="theme-color" content="hsl(339, 90%, 68%)">
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.6.0/css/all.css" integrity="sha384-aOkxzJ5uQz7WBObEZcHvV5JvRW3TUc2rNPA7pe3AwnsUohiw1Vj2Rgx2KSOkF5+h" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css" crossorigin="anonymous" title="hl-light" disabled>
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark">
        
      
    

    

    

  

  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Lato:400,700|Merriweather|Roboto+Mono">
  

  
  
  
  <link rel="stylesheet" href="/css/academic.min.0d1481abfb3d50a0a347c27b6d1ea464.css">

  

  
  
  

  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/niyomnaitham-2014/">

  
  
  
  
    
    
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="Adam La Caze">
  <meta property="og:url" content="/publication/niyomnaitham-2014/">
  <meta property="og:title" content="Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. | Adam La Caze">
  <meta property="og:description" content="BACKGROUND: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.  METHODS: We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS) subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred in May 2007. The DDD/1000 population/day were examined in a series of time-series regression analysis with the drug safety warnings specified as interventions.  RESULTS: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000 population/day in January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value &lt;0.001), however use did not significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009-2010. However, pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.  CONCLUSIONS: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation."><meta property="og:image" content="/img/icon-192.png">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2014-01-01T00:00:00&#43;10:00">
  
  <meta property="article:modified_time" content="2019-06-28T14:41:02&#43;10:00">
  

  

  

  <title>Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. | Adam La Caze</title>

</head>
<body id="top" data-spy="scroll" data-target="#TableOfContents" data-offset="71" class="dark">
  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" role="textbox" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



<nav class="navbar navbar-light fixed-top navbar-expand-lg py-0" id="navbar-main">
  <div class="container">

    
      <a class="navbar-brand" href="/">Adam La Caze</a>
      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
        <span><i class="fas fa-bars"></i></span>
      </button>
      

    
    <div class="collapse navbar-collapse" id="navbar">

      
      
      <ul class="navbar-nav mr-auto">
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#featured">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/teaching/">
            
            <span>Teaching</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        

      
      </ul>
      <ul class="navbar-nav ml-auto">
      

        

        
        <li class="nav-item">
          <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        

        
        <li class="nav-item">
          <a class="nav-link js-dark-toggle" href="#"><i class="fas fa-moon" aria-hidden="true"></i></a>
        </li>
        

      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  












  

  
  
  
<div class="article-container pt-3">
  <h1 itemprop="name">Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.</h1>

  

  
    



<meta content="2014-01-01 00:00:00 &#43;1000 AEST" itemprop="datePublished">
<meta content="2019-06-28 14:41:02 &#43;1000 AEST" itemprop="dateModified">

<div class="article-metadata">

  
  
  
  
  <div>
    



  <span itemprop="author name" itemtype="http://schema.org/Person"><a href="/authors/suvimol-niyomnaitham/">Suvimol Niyomnaitham</a></span>, <span itemprop="author name" itemtype="http://schema.org/Person"><a href="/authors/andrew-page/">Andrew Page</a></span>, <span itemprop="author name" itemtype="http://schema.org/Person"><a href="/authors/adam-la-caze/">Adam La Caze</a></span>, <span itemprop="author name" itemtype="http://schema.org/Person"><a href="/authors/karen-whitfield/">Karen Whitfield</a></span>, <span itemprop="author name" itemtype="http://schema.org/Person"><a href="/authors/alesha-j-smith/">Alesha J Smith</a></span>

  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    <time>January 2014</time>
  </span>
  

  

  

  
  

  
  

  
    
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=&amp;url="
         target="_blank" rel="noopener">
        <i class="fab fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u="
         target="_blank" rel="noopener">
        <i class="fab fa-facebook-f"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=&amp;title="
         target="_blank" rel="noopener">
        <i class="fab fa-linkedin-in"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=&amp;title="
         target="_blank" rel="noopener">
        <i class="fab fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=&amp;body=">
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3994196&amp;tool=pmcentrez&amp;rendertype=abstract" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/niyomnaitham-2014/niyomnaitham-2014.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1186/1472-6963-14-151" target="_blank" rel="noopener">
  DOI
</a>



</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">BACKGROUND: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.  METHODS: We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS) subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred in May 2007. The DDD/1000 population/day were examined in a series of time-series regression analysis with the drug safety warnings specified as interventions.  RESULTS: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.<sup>96</sup>&frasl;<sub>1000</sub> population/day in January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value &lt;0.001), however use did not significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009-2010. However, pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.  CONCLUSIONS: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>BMC Health Services Research</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    

<div class="article-tags">
  
  <a class="badge badge-light" href="/tags/adverse-drug-reaction-reporting-systems/">Adverse Drug Reaction Reporting Systems</a>
  
  <a class="badge badge-light" href="/tags/australia/">Australia</a>
  
  <a class="badge badge-light" href="/tags/australia-epidemiology/">Australia: epidemiology</a>
  
  <a class="badge badge-light" href="/tags/diabetes-mellitus/">Diabetes Mellitus</a>
  
  <a class="badge badge-light" href="/tags/type-2/">Type 2</a>
  
  <a class="badge badge-light" href="/tags/diabetes-mellitus/">Diabetes Mellitus</a>
  
  <a class="badge badge-light" href="/tags/type-2-drug-therapy/">Type 2: drug therapy</a>
  
  <a class="badge badge-light" href="/tags/drug-interactions/">Drug Interactions</a>
  
  <a class="badge badge-light" href="/tags/humans/">Humans</a>
  
  <a class="badge badge-light" href="/tags/hypoglycemic-agents/">Hypoglycemic Agents</a>
  
  <a class="badge badge-light" href="/tags/hypoglycemic-agents-adverse-effects/">Hypoglycemic Agents: adverse effects</a>
  
  <a class="badge badge-light" href="/tags/hypoglycemic-agents-therapeutic-use/">Hypoglycemic Agents: therapeutic use</a>
  
  <a class="badge badge-light" href="/tags/risk/">Risk</a>
  
  <a class="badge badge-light" href="/tags/risk-factors/">Risk Factors</a>
  
  <a class="badge badge-light" href="/tags/thiazolidinediones/">Thiazolidinediones</a>
  
  <a class="badge badge-light" href="/tags/thiazolidinediones-adverse-effects/">Thiazolidinediones: adverse effects</a>
  
  <a class="badge badge-light" href="/tags/thiazolidinediones-therapeutic-use/">Thiazolidinediones: therapeutic use</a>
  
</div>


    








  
  
    
  
  





  
  <div class="media author-card" itemscope itemtype="http://schema.org/Person">
    

    <div class="media-body">
      <h5 class="card-title" itemprop="name"><a href="/authors/suvimol-niyomnaitham/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
        
      </ul>
    </div>
  </div>




  </div>
</div>



<div class="container">
  <footer class="site-footer">
  
  <p class="powered-by">
    <a href="/privacy/">Privacy Policy</a>
  </p>
  

  <p class="powered-by">
    

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" id="back_to_top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

</div>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
        
      

      
      
    

    
    

    
    
    

    
    
    <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script>
      const search_index_filename = "/index.json";
      const i18n = {
        'placeholder': "Search...",
        'results': "results found",
        'no_results': "No results found"
      };
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.3258b3a711acd6208568ec000de4beec.js"></script>

  </body>
</html>

